Chembio to develop multiplex Point-of-Care Test for Influenza Immunity in partnership with the US CDC
M2 - Tue Nov 25, 8:50AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) on Monday reported a follow-on, milestone-based development agreement for a multiplex POC influenza immunity test utilising its patented Dual Path Platform (DPP) technology in partnership with an undisclosed company and the US Centers for Disease Control and Prevention (CDC).
CEMI: 3.98 (+0.08)
Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza Immunity
GlobeNewswire - Mon Nov 24, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the United States Centers for Disease Control and Prevention (CDC), for a multiplex POC influenza immunity test utilizing Chembio's patented Dual Path Platform (DPP) technology.
CEMI: 3.98 (+0.08)
Cepheid receives grant to develop Ebola test
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 7:11AM CST
CPHD: 53.39 (+0.51), CEMI: 3.98 (+0.08)
Chembio Diagnostics' (CEMI) CEO John Sperzel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:04AM CST
CEMI: 3.98 (+0.08)
Chembio Diagnostics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:56AM CST
CEMI: 3.98 (+0.08)
Chembio Diagnostics Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
CEMI: 3.98 (+0.08)
Chembio to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November 6, 2014
ACCESSWIRE - Wed Nov 05, 3:57PM CST
MEDFORD, NY / ACCESSWIRE / November 5, 2014 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, November 6, 2014 at 10:00 AM Eastern Time.
CEMI: 3.98 (+0.08)
Chembio HIV 1/2 rapid test gets CLIA waiver
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 2:58PM CST
CEMI: 3.98 (+0.08)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:18AM CDT
KNDI: 12.90 (+0.99), ALU: 3.67 (+0.03), CDTI: 1.87 (+0.01), VSR: 3.01 (-0.03), NBG: 1.95 (+0.06), ARAY: 7.54 (+0.19), GLUU: 4.07 (-0.04), OCLS: 1.50 (+0.01), CEMI: 3.98 (+0.08), TTWO: 28.60 (+0.18), PRXL: 56.48 (+0.57), RDN: 16.78 (+0.18), BBD: 13.28 (+0.05), NVAX: 5.81 (+0.18), APT: 2.55 (-0.03), BBSI: 28.34 (+0.38), LAKE: 8.94 (+0.07), GOL: 5.16 (-0.04), TASR: 26.86 (+0.84), AUY: 3.89 (+0.15), PCRX: 92.09 (-1.79), ITUB: 13.10 (+0.21)
Chembio's DPP(R) HIV 1/2 Assay Receives CLIA Waiver From FDA
GlobeNewswire - Thu Oct 30, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests and technology, today announced that the U.S. Food and Drug Administration (FDA) granted a CLIA Waiver for the Company's DPP HIV 1/2 Assay. Chembio's DPP HIV 1/2 Assay was FDA-approved previously, and the CLIA Waiver will allow Chembio to expand into important new channels that are closest to patient care including physician-office-lab (POL) facilities, clinics and other community healthcare providers.
CEMI: 3.98 (+0.08)
Chembio to develop POC diagnostic tests for dengue fever virus and specific type of cancer with DPP technology
M2 - Wed Oct 29, 5:25AM CDT
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) reported on Tuesday the launch of agreements to develop a POC diagnostic test to detect dengue fever virus plus a POC diagnostic test for a type of cancer.
CEMI: 3.98 (+0.08)
Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 10.11 (+0.25), TRNX: 25.68 (+0.13), DRRX: 0.81 (-0.01), CEMI: 3.98 (+0.08), PBCP: 10.46 (-0.04), PTIE: 2.01 (-0.02), AMDA: 0.64 (-0.01)
Chembio Announces Agreements to Develop Point-of-Care Diagnostic Tests for Dengue Fever Virus and a Specific Type of Cancer
GlobeNewswire - Tue Oct 28, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that on October 27, 2014 it entered into an agreement to develop a POC diagnostic test for dengue fever virus. The Company also announced that it has entered into an agreement with an international diagnostics company to develop a POC diagnostic test for a type of cancer. Both development projects will incorporate Chembio's patented DPP technology. Under the terms of the agreements, financial details and the names of the collaborators are not being disclosed.
CEMI: 3.98 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT
GFA: 1.52 (-0.04), FST: 0.34 (-0.02), ZAZA: 3.20 (+0.70), EBR: 2.09 (+0.01), VTAE: 19.20 (+0.02), XGTI: 0.95 (-0.04), VBIV: 3.06 (-0.14), DRRX: 0.81 (-0.01), CEMI: 3.98 (+0.08), PBR: 7.60 (-0.11), CBDE: 0.90 (+0.06), OMEX: 0.99 (+0.02), LAYN: 10.11 (+0.25), SRPT: 13.88 (+0.47), CNIT: 3.58 (+0.07), AKBA: 11.23 (-0.31), CTP: 14.57 (-0.18), VPCO: 1.30 (-0.01), PTIE: 2.01 (-0.02)
Chembio Partners With Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness
GlobeNewswire - Mon Oct 27, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an exclusive agreement with Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.
CEMI: 3.98 (+0.08)
Chembio reports November 6
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 12:14PM CDT
CEMI: 3.98 (+0.08)
Chembio to Host Conference Call to Discuss Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the third quarter of 2014, before the opening of the market on Thursday, November 6, 2014. The Company's 10-Q and earnings press release will be available at 9:15a.m. on our web site.
CEMI: 3.98 (+0.08)
Chembio Diagnostics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 8:31AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the second quarter ended June 30, 2014.
CEMI: 3.98 (+0.08)